A groundbreaking study shows that GLP-1 diabetes drugs may reduce the risk of obesity-related cancers by 7% compared to DPP-4 inhibitors, particularly in women. Discover the implications for diabetes treatment!
New research reveals that silencing hyperactive AgRP neurons in the brain could reverse type 2 diabetes without affecting weight or diet. This groundbreaking study challenges existing beliefs and points to new treatment avenues.
A groundbreaking study reveals semaglutide, already known for weight loss and diabetes treatment, is effective for fatty liver disease, benefiting two-thirds of participants in a recent trial. This could revolutionize treatment options!
Novo Nordisk's diabetes pill Rybelsus has shown significant cardiovascular benefits, reducing the risk of heart-related issues by 14%. This could offer a new, convenient treatment option for many patients.
Eli Lilly is set to unveil results from trials of orforglipron, its groundbreaking once-daily obesity pill, potentially revolutionizing weight loss treatment by offering a needle-free alternative. Analysts predict it could capture a significant share of the $150 billion GLP-1 market.
